Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue European Journal of Cancer Année : 2019

Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme

Daniel Pissaloux
  • Fonction : Auteur
  • PersonId : 768539
  • IdRef : 17847147X
Olivier Trédan
Jérôme Long
Jean-Yves Blay

Résumé

Objectives The objectives of this study were to identify actionable genomic alterations in the gynaecological subpopulation of the ProfiLER programme and to report clinical efficacy of recommended targeted treatment (RTT). Methods The ProfiLER programme (NCT01774409) is a multicentric prospective trial aiming to implement molecular profiling in patients with advanced refractory cancers. In this programme, tumour DNA is analysed by targeted next-generation sequencing (69 genes) and by whole genome array comparative genomic hybridisation. Clinical cases and genomic profiles are presented in a dedicated molecular tumour board to guide treatment strategies. We report here an analysis of patients with gynaecological cancers included in this trial. Results From February 2013 to February 2017, 309 patients with gynaecologic cancer were included; 279 (90%) had sufficient quality, and 131 patients (42.4%) had at least one actionable genomic alteration in cancer cells. Four alterations were shared by at least 3% of the patients: 27 (9.7%) PIK3CA mutations, 15 (5.4%) KRAS mutations, 11 (3.9%) ERBB2 amplifications and 9 (3.2%) CDKN2A deletions. Forty-one treatments were initiated among 39 patients (12.6% of the screened population): 8 (20%) had a partial response, and other 10 (24%) had a stable disease. The median progression-free survival was 2.7 months. The median overall survival was 15.6 months for patients who received a RTT. Conclusion Molecular profiling identified actionable alterations in 42.4% of patients with advanced refractory gynaecologic cancer, but only 12.6% were treated with a RTT. Among them, 46% derived clinical benefit (5.8% of the screened population).
Fichier principal
Vignette du fichier
S0959804919303855.pdf (729.22 Ko) Télécharger le fichier
Origine : Fichiers produits par l'(les) auteur(s)

Dates et versions

hal-03487380 , version 1 (21-12-2021)

Licence

Paternité - Pas d'utilisation commerciale

Identifiants

Citer

Romain Varnier, Olivia Le Saux, Sylvie Chabaud, Gwenaëlle Garin, Emilie Sohier, et al.. Actionable molecular alterations in advanced gynaecologic malignancies: updated results from the ProfiLER programme. European Journal of Cancer, 2019, 118, pp.156 - 165. ⟨10.1016/j.ejca.2019.06.017⟩. ⟨hal-03487380⟩
21 Consultations
66 Téléchargements

Altmetric

Partager

Gmail Facebook X LinkedIn More